Stronger H1 FY2026 Performance Upward Revision to Guidance

• Upgraded FY26 adjusted EBITDA guidance to $16.5 million - $19.0 million
• H1 FY26 adjusted EBITDA of $8.3 million, a significant increase on the $3.7 million in the prior corresponding period
• FY26 revenue guidance unchanged at $65 million - $75 million, with H1 FY26 revenue of $31.3 million

Bioxyne Limited (ASX: BXN) ('Bioxyne' or 'the Company') is pleased to announce an upgrade to its FY26 adjusted EBITDA guidance, reflecting a stronger than expected first half performance and continued margin improvement. The company delivered an adjusted EBITDA of $8.3 million for H1 FY26, a substantial improvement on the $3.7 million achieved in the prior corresponding period. The uplift reflects successful margin expansion initiatives and efficient scaling of the business while revenue tracked in line with expectations. FY26 revenue guidance remains unchanged at $65 million to $75 million. Chief Executive Officer Sam Watson commented: 'This earnings upgrade reflects the work done to improve margins and scale the business efficiently. With revenue tracking in line with our expectations, and profitability well ahead of where we anticipated, we are well positioned to deliver a strong full year result.'

Upgraded FY26 adjusted EBITDA guidance to $16.5 million - $19.0 million (previously $11.5 million - $13.5 million)